TNFSF11 and metastatic neoplasm: This section will review the pre-clinical evidence that led to the discovery of RANKL-mediated breast carcinogenesis and characterization of RANK-expressing BCa, as well as the clinical evidence of RANKL inhibition in BCa bone metastatic disease treatment and prevention.